Numinus has shared an update on its MDMA-assisted therapy for PTSD trial, which is being pursued in collaboration with MAPS Public Benefit Corp. Following the successful completion of a number of milestones – including the recruitment of therapists, physicians, and staff – the trial has advanced to the pre-implementation stage at the company’s Vancouver clinic. Initial meetings with Health Canada…

Source

Previous articleRed Light Holland Receives Receipt for Final Short-form Prospectus for Previously Announced $10 Million Bought Deal Public Offering
Next articleMindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company